• New

Ovitrelle 250 mcg


Manufacturer: Merck, Holland. 

Substance: choriogonadotropin alfa.

Package: 0.5ml pre-filled syringe (250 mcg).


Ovitrelle is indicated in the treatment of

Adult women undergoing superovulation prior to assisted reproductive technologies (ART) such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth,

Anovulatory or oligo-ovulatory adult women: Ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory women after stimulation of follicular growth.

In men, it help address the symptoms of hypogonadism, such as low testosterone and infertility. Can help the body increase its production of testosterone and sperm, which can help reduce infertility.

Specific References